Cracking the Code of Immunotherapy Resistance in SCLC: Molecular Insights and Emerging Solutions - PubMed
4 hours ago
- #molecular subtypes
- #immunotherapy resistance
- #small cell lung cancer
- Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with poor prognosis.
- Immune checkpoint inhibitors (ICIs) show modest improvement in SCLC survival despite high tumor mutational burden.
- Resistance mechanisms include tumor-intrinsic immune escape and immunosuppressive tumor microenvironment.
- SCLC molecular subtypes reveal distinct immunogenic landscapes with potential predictive value for immunotherapy response.
- Ongoing clinical trials explore combination ICI regimens and novel strategies like epigenetic modulators and bispecific T-cell engagers.
- Precision immunotherapy roadmap suggests biomarker-guided and subtype-stratified clinical trial design.